Last updated: October 28th, 2025
The EU Joint Clinical Assessment (JCA) reshapes how pharmaceutical teams prepare for market access. As all new medicines will undergo assessment by 2030, companies must act early, integrating JCA considerations into clinical planning, evidence strategies, and launch readiness. We help teams anticipate PICO scenarios, align trials with JCA expectations, as well as minimize launch risk through strategic planning and cross-functional collaboration.
What Is the Joint Clinical Assessment (JCA)?
The EU Joint Clinical Assessment (JCA) is part of the EU Health Technology Assessment Regulation (EU 2021/2282), designed to create a single, standardized review of clinical evidence for new medicines across all EU member states (European Commission, 2025). It focuses on clinical effectiveness, safety, and comparative outcomes, replacing the need for multiple national assessments of the same data.
The EU will implement the JCA in stages, beginning in 2025 for oncology and advanced therapy medicinal products (ATMPs), expanding in 2028 to orphan and other innovative medicines, and applying to all new medicines by 2030 (European Commission, 2025).
With a significant procedural shift, it defines the baseline clinical evidence required for EU market access and influences the pace and consistency of national reimbursement decisions.
Why JCA Readiness Matters
-
Market Access Dependence: Without JCA compliance, access to EU markets could be delayed or denied.
-
Early Evidence Planning: Market access planning should begin during strategic phases, ideally before pivotal trial designs are finalized.
-
Comparative Value Assessment: Preparing for indirect treatment comparisons early will be essential to demonstrate relative benefit.
-
Cross-Functional Coordination: Align clinical, regulatory, market access, and HEOR efforts so JCA expectations are built into every stage of development.
-
Competitive Advantage: Teams that plan early and embed JCA requirements into trial design will be better positioned for timely and consistent reimbursement decisions.
Key Steps Pharma Teams Must Take for JCA Readiness
1. Anticipate PICO Scenarios Early
JCA assessments follow the Population, Intervention, Comparator, and Outcomes (PICO) framework. Pharma teams need to:
- Predict potential comparator choices across EU countries and align with current standards of care.
- Identify the payer-relevant outcomes most likely to be requested for the therapy.
- Reassess and refine PICO assumptions regularly and continually adjust as practice patterns and policies evolve.
This early, iterative approach ensures trials generate data aligned with anticipated JCA requirements and reduces the need for adjustments late in development.
2. Integrate JCA Into Clinical Trial Design
Embedding JCA requirements into clinical development ensures pivotal studies produce evidence that aligns with anticipated assessment needs. Companies should:
Incorporate JCA considerations early in trial design so studies are structured around expected PICO elements.
Participate in joint scientific consultations to confirm endpoints and comparators meet HTA expectations.
Plan for indirect treatment comparisons (ITCs) through early feasibility reviews and protocol designs that enable reliable cross-trial analyses.
Select comparators consistent with current standards of care across key EU markets.
3. Build a Cross-Functional JCA Team
Success requires collaboration across functions:
- Clinical development to ensure trial design readiness
- Market access & HEOR to align with payer evidence needs
- Regulatory affairs to integrate EMA and JCA requirements
- Commercial for launch readiness procedures
- Internal training to equip teams with a consistent understanding of JCA requirements
Ensure JCA requirements are integrated in all decisions and deliverables.
4. Map the JCA Timeline
The first wave of JCA requirements begins in 2025 for oncology and advanced therapy medicinal products (ATMPs), expanding to all medicines by 2030. Pharma teams must:
Align planning across EMA and EU-HTA milestones to keep regulatory and assessment activities moving in step.
Build in adequate lead time for dossier development, as teams must typically submit JCA materials several weeks before the EMA CHMP opinion.
Anticipate quick review cycles and internal workload peaks, ensuring teams are prepared to respond efficiently to requests.
Maintain close coordination between global, regional, and local teams and incorporate JCA outcomes smoothly into national HTA and reimbursement submissions.
5. Partner With Experts
Navigating JCA is complex. Partnering with specialist experts can help companies:
Simulate potential PICO scenarios and anticipate EU market variations through integrated strategic planning.
Align global, regional, and local perspectives so evidence strategies and launch plans remain connected across markets.
Support feasibility assessments, dossier preparation, and methodological alignment and meet evolving JCA standards.
Facilitate communication and coordination across internal and external stakeholders and streamline every stage of the JCA process.
6. Use AI Tools Like PICO Predict to Simulate PICO Scenarios
Preparing for JCA means managing uncertainty in European comparator choices and outcome measures. This is where PICO Predict comes in.
Custom-tailored scenario modeling: AI predicts and validates PICO configurations for specific assets and markets.
Live evidence-synthesis updates: Systematic literature reviews (SLRs) and data-generation plans can be refreshed as the treatment landscape changes.
Seamless integration into submissions: AI-driven outputs feed directly into JCA evidence packages, ensuring alignment across regulatory, market access, and HEOR teams.
As a result, by integrating tools like PICO Predict early, pharma teams can design trials more confidently, anticipate country-specific divergences, and accelerate their path to positive JCA outcomes.
Don’t Wait Until 2028
JCA is not just a regulatory checkbox; it’s a strategic shift in how pharma companies must plan for EU launches. By anticipating PICO, aligning trials, and collaborating across functions, companies can secure earlier access, smoother reimbursement, and stronger competitive positioning.
Is your team JCA ready? Connect with our experts to build a tailored JCA readiness roadmap and reduce launch risk.
Request Your Complimentary JCA Readiness Assessment
To learn more about JCA, please visit:
Meet our JCA Expert
Esther Nzenza
Senior Partner, Global Value and Market Access
Esther founded Decisive Consulting in 2020 following 23 years’ experience in the pharmaceutical and biotechnology industry at national, regional, and international levels. Over her career, Esther has built and led Market Access and HEOR organizations and has additionally led all commercial functions across international markets. She is best known for her ability to solve complex problems, from optimizing organizational ways of working to addressing specific external challenges and finding hidden opportunities. Recently recognized as “One to Watch” in the 2024 Times and LDC Top 50 Most Ambitious Business Leaders awards, Esther is passionate about diversity and inclusion and champions “rebel thinking” to uncover new possibilities.
FAQs on JCA Readiness
When does JCA become mandatory?
From 2025 for oncology and ATMPs, and by 2030 for all new medicines.
How is JCA different from EMA approval?
EMA approval covers safety and efficacy, while JCA focuses on comparative clinical effectiveness for payer decisions.
What happens if we’re not JCA-ready?
Delays in reimbursement and access, potentially leading to lost market share.
Do national HTAs still matter?
Yes, countries will still evaluate cost-effectiveness and pricing, but JCA evidence is the foundation.
What’s the first step toward readiness?
Integrating JCA considerations into Phase II/III trial design and forming a cross-functional evidence team.
How can companies prepare organizationally for JCA?
Assign JCA leadership, close capability gaps, and build internal expertise early.
Why are stakeholder engagement and monitoring regulations important?
It ensures evidence meets EU and local needs while complying with evolving HTA rules.
Reference:
Are you #JCAReady? — Decisive Consulting
Additional References:
European Commission. (2025). Joint Clinical Assessments — Implementation of the Health Technology Assessment Regulation (EU 2021/2282). Health Technology Assessment. Retrieved October 2025, from https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment_en
List of ongoing joint clinical assessments: https://health.ec.europa.eu/document/download/d947533e-7e4e-4e82-a9c6-e06830d708f8_en?filename=hta_ongoing-jca_en.xlsx